These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32617743)

  • 1. Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas.
    Cordova C; Kurz SC
    Curr Oncol Rep; 2020 Jul; 22(8):84. PubMed ID: 32617743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
    Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
    Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
    Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
    Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular alterations in meningioma: prognostic and therapeutic perspectives.
    Birzu C; Peyre M; Sahm F
    Curr Opin Oncol; 2020 Nov; 32(6):613-622. PubMed ID: 32890025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic/molecular alterations of meningiomas and the signaling pathways targeted.
    Domingues P; González-Tablas M; Otero Á; Pascual D; Ruiz L; Miranda D; Sousa P; Gonçalves JM; Lopes MC; Orfao A; Tabernero MD
    Oncotarget; 2015 May; 6(13):10671-88. PubMed ID: 25965831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role and regulatory mechanism of IL-1β on the methylation of the NF2 gene in benign meningiomas and leptomeninges.
    Wang B; Cui Z; Zhong Z; Sun Y; Yang GY; Sun Q; Bian L
    Mol Carcinog; 2016 Dec; 55(12):2268-2277. PubMed ID: 26840621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational patterns and regulatory networks in epigenetic subgroups of meningioma.
    Paramasivam N; Hübschmann D; Toprak UH; Ishaque N; Neidert M; Schrimpf D; Stichel D; Reuss D; Sievers P; Reinhardt A; Wefers AK; Jones DTW; Gu Z; Werner J; Uhrig S; Wirsching HG; Schick M; Bewerunge-Hudler M; Beck K; Brehmer S; Urbschat S; Seiz-Rosenhagen M; Hänggi D; Herold-Mende C; Ketter R; Eils R; Ram Z; Pfister SM; Wick W; Weller M; Grossmann R; von Deimling A; Schlesner M; Sahm F
    Acta Neuropathol; 2019 Aug; 138(2):295-308. PubMed ID: 31069492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
    Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C
    Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas.
    Rutland JW; Gill CM; Loewenstern J; Arib H; Pain M; Umphlett M; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Shrivastava RK; Fowkes M
    Cancer Immunol Immunother; 2021 Jan; 70(1):169-176. PubMed ID: 32661686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of genetic alterations and methylation classes in meningioma.
    Berghoff AS; Hielscher T; Ricken G; Furtner J; Schrimpf D; Widhalm G; Rajky U; Marosi C; Hainfellner JA; von Deimling A; Sahm F; Preusser M
    Brain Pathol; 2022 Mar; 32(2):e12970. PubMed ID: 35213082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic landscape of meningioma.
    Yuzawa S; Nishihara H; Tanaka S
    Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological classification and molecular genetics of meningiomas.
    Mawrin C; Perry A
    J Neurooncol; 2010 Sep; 99(3):379-91. PubMed ID: 20809251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical potential of meningioma genomic insights: a practical review for neurosurgeons.
    Karsy M; Azab MA; Abou-Al-Shaar H; Guan J; Eli I; Jensen RL; Ormond DR
    Neurosurg Focus; 2018 Jun; 44(6):E10. PubMed ID: 29852774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-grade meningiomas: biology and implications.
    Bi WL; Prabhu VC; Dunn IF
    Neurosurg Focus; 2018 Apr; 44(4):E2. PubMed ID: 29606053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Meningiomas: new prognostic factors].
    Sanz Esponera J
    An R Acad Nac Med (Madr); 2007; 124(2):319-32; discussion 330-2. PubMed ID: 18069599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
    Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
    Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management.
    Daoud EV; Zhu K; Mickey B; Mohamed H; Wen M; Delorenzo M; Tran I; Serrano J; Hatanpaa KJ; Raisanen JM; Snuderl M; Cai C
    Acta Neuropathol Commun; 2022 Apr; 10(1):56. PubMed ID: 35440040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific.
    Jun P; Hong C; Lal A; Wong JM; McDermott MW; Bollen AW; Plass C; Held WA; Smiraglia DJ; Costello JF
    Neuro Oncol; 2009 Aug; 11(4):414-22. PubMed ID: 19001526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus.
    Hansson CM; Buckley PG; Grigelioniene G; Piotrowski A; Hellström AR; Mantripragada K; Jarbo C; Mathiesen T; Dumanski JP
    BMC Genomics; 2007 Jan; 8():16. PubMed ID: 17222329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatment options for meningioma.
    Apra C; Peyre M; Kalamarides M
    Expert Rev Neurother; 2018 Mar; 18(3):241-249. PubMed ID: 29338455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.